There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition.
In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development.
This webinar, Enhancing the predictability of preclinical development, hosted by DDW and supported by PerkinElmer, took place on 26 May.
Dr. Seyoum Ayehunie, Vice President, Scientific Research and Development, MatTek Corporation, will discuss the functionality and limitations of a novel in vitro 3D primary human cell-based tissue model for drug toxicity and efficacy studies.
This talk will be followed by a presentation from Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals, (pictured), who will explain why developing a predictive pre-clinical assay is key to success in immuno-oncology drug development.
Key Learning Objectives:
- How to evaluate models to establish robust and reliable preclinical investigation of drug candidates prior to entering clinical trials
- How to gain an understanding of the advancements in preclinical model systems and assays
- What to consider from the latest innovations and impact on bioanalytical assays
Who Should Attend:
- Preclinical development scientists
- Pharmacologists
- Toxicologists
- Bioanalytical assay development scientists
- Analytical scientists
Watch on demand for free here.
